Antigenics, Inc. (AGEN)

I'm just climbing aboard this train. Here's this morning's CNBC article: http://www.cnbc.com/id/24010964/site/14081545?__source=yahoo|headline|quote|text|&par=yahoo

"A test showed that a subset of patients on the company's kidney cancer drug Oncophage lived 1.7 years longer without the cancer coming back. But because the clinical trial didn't meet its main goal and the aforementioned benefit was only discovered in a re-analysis of the data, the drug didn't pass muster with the Food and Drug Administration. The FDA wanted AGEN to do a bigger, longer and expensive study. But like most baby biotechs, Antigenics didn't have that kind of cash. So, the company turned to Russia where it had enrolled 125 patients in the same clinical trial. And after a 10-month process, AGEN won approval of the drug there, making Russia the first country in the world to allow a therapeutic cancer vaccine onto the market.

"It's not a huge market in terms of rubles or dollars, but it's a big, fast-growing untreated population. The lead clinical trial investigator, Dr. Christopher Wood at the MD Anderson Cancer Center, says the company has given him verbal assurances that it will use the Russian revenue to pay for another study here that might eventually satisfy the FDA. Dr. Wood, an associate professor of urology and cancer biology, says he doesn't own AGEN stock--he just consults for Antigenics and ran the clinical trial.

"If you're wondering if Americans will be able to go to Russia for Oncophage treatment, Antigenics Chairman and CEO Garo Armen told me he doesn't know yet if, or how, that might work."